Restoring value to stalled Phase II compounds: the case for developing a novel compound for depression using pharmacogenetics.

@article{Reed2005RestoringVT,
  title={Restoring value to stalled Phase II compounds: the case for developing a novel compound for depression using pharmacogenetics.},
  author={Carol T. Reed and Matthew W. Kalnik and Kevin Rakin and Maria Athanasiou and Richard Judson},
  journal={Pharmacogenomics},
  year={2005},
  volume={6 2},
  pages={95-100}
}